ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CTLA-4 Monoclonal Antibody IBI310

Also written as “IBI310”, “IBI310&Sintilimab” and “IBI310 (anti-CTLA-4 antibody)”.

Its studies are mostly in Carcinoma, Hepatocellular · Colorectal Neoplasms · Uterine Cervical Neoplasms · Biliary Tract Neoplasms · Melanoma, led by Innovent Biologics.

Drug pageAnti-CTLA-4 Monoclonal Antibody IBI310: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 18, 202011 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics112 open or runningphase 3since Feb 18, 2020May 10, 2018Dec 31, 2027phase 3 · NCT07490262

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03545971 · 53 enrolled · China
  2. Feb 4, 2020Phase 2 study in Colorectal NeoplasmsNCT04258111 · 4 enrolled · China
  3. Feb 18, 2020Phase 3 study in Acral Melanoma That Has Been Removed by SurgeryNCT04277663 · 136 enrolled · China
  4. Oct 12, 2020Phase 2 study in Advanced Cervical CancerNCT04590599 · 205 enrolled · China
  5. Jan 13, 2021Phase 3 study in Carcinoma, HepatocellularNCT04720716 · 344 enrolled · China
  6. Apr 23, 2021Phase 1 study in Healthy SubjectsNCT04868760 · 148 enrolled · China
  7. Jun 7, 2021Phase 1 study in NPCNCT04945421 · 30 enrolled · China
  8. Nov 1, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05118334 · 30 enrolled · China
  9. Dec 6, 2022Phase 2 study in Advanced Biliary Tract CancerNCT05653180 · 20 enrolled · China
  10. May 26, 2023Phase 3 study in MSI-HNCT05890742 · 453 enrolled · China
  11. Mar 16, 2026Phase 3 study in Carcinoma, HepatocellularNCT07490262 · 680 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Carcinoma, HepatocellularNCT07490262
  2. Apr 15, 2028Primary completion: phase 3 study in MSI-HNCT05890742

TargetBeta

CTLA4 →read by rule
“A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), ”NCIt, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07490262Carcinoma, Hepatocellular · China3RecruitingDec 31, 2027680
NCT05890742MSI-H · China3Active, not recruitingApr 15, 2028453
NCT05653180Advanced Biliary Tract Cancer · China2UNKNOWNDec 31, 202320
NCT05118334Carcinoma, Non-Small-Cell Lung · China1CompletedJul 31, 202230
NCT04945421NPC · China1CompletedApr 25, 202230
NCT04868760Healthy Subjects · China1CompletedMay 2, 2022148
NCT04720716Carcinoma, Hepatocellular · China3CompletedDec 31, 2025344
NCT04590599Advanced Cervical Cancer · China2CompletedNov 20, 2023205
NCT04277663Acral Melanoma That Has Been Removed by Surgery · China3TerminatedFeb 28, 2023136
NCT04258111Colorectal Neoplasms · China2TerminatedOct 26, 20204
NCT03545971Advanced Solid Tumors · China1CompletedSep 10, 202153

How it is read

Names in the registry

  • “IBI310”, 8 entries
  • “IBI310&Sintilimab”, 1 entry
  • “IBI310 (anti-CTLA-4 antibody)”, 1 entry
  • “IBI310+IBI308”, 1 entry

Codes read as this program: IBI310.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.